... For patients with disease localised to the stomach, concomitant follow-up with imaging (e.g. with computerised tomography) offers no additional benefit in the majority of cases. Response rates to antibiotic therapy can be slow. Therefore, escalation to chemotherapy or ...

... at least 2 weeks before their screening evaluation. Concomitant treatment with stable dosages of dopamine agonists, amantadine hydrochloride, anticholinergics, and entacapone was allowed (no duration given). Trenkwalder C, Kies B, Rudzinska M, Fine J, ...

... or preoperative lapatinib plus trastuzumab. This anti-HER2 therapy was given alone for 6 weeks and then weekly paclitaxel was added to the regimen for an additional 12 weeks. The primary endpoint of this study ...

... e.g. noncardiogenic pulmonary edema); health care utilization indicators (e.g., ... Question 4 : Additional outcomes are rates of linkage to treatment for ...

... the treatment. Variables that change in response to treatment and post-randomization ... (4) concomitant exposures (e.g., beta-blockers, aspirin); and (5) ...

... quality for harms reporting. Table 40 Harms in ... and 25 were receiving concomitant stimulants. More children in the placebo group (76. ...

... of the time. Patients may want to consider additional therapy, such as radiation therapy and chemotherapy, or wide ... CLB-8984. Patients with T1 tumors received no additional treatment after surgery, whereas patients with T2 tumors were ...

... of TSH are expected to remain low during therapy, given the central nature of this deficiency. Central hypothyroidism ... g., age, genetic susceptibility, renal function); receipt of additional ototoxic therapy (cranial radiation therapy, aminoglycosides, loop diuretics), and the ...

... Information on the health care provider, treatment facility, concomitant therapies, or insurance may also be considered. Unknown confounders, ... artery bypass graft) and may include information on concomitant treatments. Dosage (or parameters for devices), route of administration, ...

... the SOE for outcomes comparing aromatherapy and control treatment. Given the potential risk of bias, small study size, ... to its short serum half-life and narrow therapeutic range, oxytocin is given as a continuous intravenous infusion and begun at ...